Author Archives: admin


Stem Cell Clinic > Articles by: admin

Worldwide Cell Therapy Industry to 2027 – Profiling Allosource, Medipost and Mesoblast Among Others – PRNewswire

By Embryonic Stem Cells

DUBLIN, Feb. 9, 2021 /PRNewswire/ -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market accounted for $7,754. 89 million in 2019, and is expected to reach $48,115. 40 million by 2027, registering a CAGR of 25. 6% from 2020 to 2027.

Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient's body to replace diseased or missing ones.

This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures.

Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the market for cell therapy.

In addition, growth in aging patient population, The rise in cell therapy transplantations globally, and surge in disease awareness drive growth of the global cell therapy market. Furthermore, The rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and increase in incidences of diseases such as cancer, cardiac abnormalities, and organ failure are the key factors that drive growth of the global market.

Moreover, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in the future.

The global cell therapy market is categorized on the basis of therapy type, therapeutic area, cell type, end user, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutics, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.

The global cell therapy market is categorized on the basis of therapy type, therapeutic, cell type, end user and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutic area, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. On the basis of cell type, it is segregated into stem cell therapy and non-stem cell type. On the basis of end user, it is segregated into hospital & clinics and academic & research institutes. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

Key Topics Covered:

Chapter 1: Introduction 1.1. Report Description 1.2. Key Benefits for Stakeholders 1.3. Key Market Segments 1.4. Research Methodology 1.4.1. Secondary Research 1.4.2. Primary Research 1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary 2.1. Key Findings of the Study 2.2. Cxo Perspective

Chapter 3: Market Overview 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top Player Positioning 3.2.2. Top Investment Pockets 3.2.3. Top Winning Strategies 3.3. Porter's Five Forces Analysis 3.4. Impact Analysis 3.4.1. Drivers 3.4.1.1. Technological Advancements in the Field of Cell Therapy 3.4.1.2. The Rise in Number of Cell Therapy Clinical Studies 3.4.1.3. The Rise in Adoption of Regenerative Medicine 3.4.2. Restraint 3.4.2.1. Developing Stage and Pricing 3.4.3. Opportunity 3.4.3.1. High Growth Potential in Emerging Markets 3.5. Impact of Covid-19 on Cell Therapy Market

Chapter 4: Cell Therapy Market, by Cell Type 4.1. Overview 4.1.1. Market Size and Forecast 4.2. Stem Cell 4.2.1. Key Market Trends and Opportunities 4.2.2. Market Size and Forecast, by Region 4.2.3. Market Size and Forecast, by Type 4.2.3.1. Bone Marrow, Market Size and Forecast 4.2.3.2. Blood, Market Size and Forecast 4.2.3.3. Umbilical Cord-Derived, Market Size and Forecast 4.2.3.4. Adipose-Derived Stem Cell, Market Size and Forecast 4.2.3.5. Others (Placenta, and Nonspecific Cells), Market Size and Forecast 4.3. Non-Stem Cell 4.3.1. Key Market Trends and Opportunities 4.3.2. Market Size and Forecast, by Region

Chapter 5: Cell Therapy Market, by Therapy Type 5.1. Overview 5.1.1. Market Size and Forecast 5.2. Autologous 5.2.1. Key Market Trends and Opportunities 5.2.2. Market Size and Forecast, by Region 5.2.3. Market Analysis, by Country 5.3. Allogeneic 5.3.1. Key Market Trends and Opportunities 5.3.2. Market Size and Forecast, by Region 5.3.3. Market Analysis, by Country

Chapter 6: Cell Therapy Market, by Therapeutic Area 6.1. Overview 6.1.1. Market Size and Forecast 6.2. Malignancies 6.2.1. Market Size and Forecast, by Region 6.2.2. Market Analysis, by Country 6.3. Musculoskeletal Disorders 6.3.1. Market Size and Forecast, by Region 6.3.2. Market Analysis, by Country 6.4. Autoimmune Disorders 6.4.1. Market Size and Forecast, by Region 6.4.2. Market Analysis, by Country 6.5. Dermatology 6.5.1. Market Size and Forecast, by Region 6.5.2. Market Analysis, by Country 6.6. Others 6.6.1. Market Size and Forecast, by Region 6.6.2. Market Analysis, by Country

Chapter 7: Cell Therapy Market, by End-user 7.1. Overview 7.1.1. Market Size and Forecast 7.2. Hospitals & Clinics 7.2.1. Key Market Trends and Opportunities 7.2.2. Market Size and Forecast, by Region 7.2.3. Market Analysis, by Country 7.3. Academic & Research Institutes 7.3.1. Key Market Trends and Opportunities 7.3.2. Market Size and Forecast, by Region 7.3.3. Market Analysis, by Country

Chapter 8: Cell Therapy Market, by Region 8.1. Overview 8.2. North America 8.3. Europe 8.4. Asia-Pacific 8.5. LAMEA

Chapter 9: Company Profiles 9.1. Allosource 9.1.1. Company Overview 9.1.2. Company Snapshot 9.1.3. Operating Business Segments 9.1.4. Product Portfolio 9.1.5. Key Strategic Moves and Developments 9.2. Cells for Cells 9.2.1. Company Overview 9.2.2. Company Snapshot 9.2.3. Operating Business Segments 9.2.4. Product Portfolio 9.3. Holostem Terapie Avanzate Srl 9.3.1. Company Overview 9.3.2. Company Snapshot 9.3.3. Operating Business Segments 9.3.4. Product Portfolio 9.4. Jcr Pharmaceuticals Co. Ltd. 9.4.1. Company Overview 9.4.2. Company Snapshot 9.4.3. Operating Business Segments 9.4.4. Product Portfolio 9.4.5. Business Performance 9.4.6. Key Strategic Moves and Developments 9.5. Kolon Tissuegene, Inc. 9.5.1. Company Overview 9.5.2. Company Snapshot 9.5.3. Operating Business Segments 9.5.4. Product Portfolio 9.5.5. Key Strategic Moves and Developments 9.6. Medipost Co. Ltd. 9.6.1. Company Overview 9.6.2. Company Snapshot 9.6.3. Operating Business Segments 9.6.4. Product Portfolio 9.6.5. Business Performance 9.7. Mesoblast Ltd 9.7.1. Company Overview 9.7.2. Company Snapshot 9.7.3. Operating Business Segments 9.7.4. Product Portfolio 9.7.5. Business Performance 9.8. Nuvasive, Inc. 9.8.1. Company Overview 9.8.2. Company Snapshot 9.8.3. Operating Business Segments 9.8.4. Product Portfolio 9.8.5. Business Performance 9.9. Osiris Therapeutics, Inc. 9.9.1. Company Overview 9.9.2. Company Snapshot 9.9.3. Operating Business Segments 9.9.4. Product Portfolio 9.10. Stemedica Cell Technologies, Inc. 9.10.1. Company Overview 9.10.2. Company Snapshot 9.10.3. Operating Business Segments 9.10.4. Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/shw12n

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

More here:
Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others - PRNewswire

Protein Discovery in the Development of New Hearing Hair Cells Could Lead to Treatments for Hearing Loss – SciTechDaily

By Stem Cell Treatment

A surface view of the organ of hearing (cochlea) from a mouse, using confocal microscopy. The sensory cells are named hair cells because of their apical projections (stereocilia) which move from stimulation by sound. Credit: University of Maryland School of Medicine

Researchers at the University of Maryland School of Medicine (UMSOM) have conducted a study that has determined the role that a critical protein plays in the development of hair cells. These hair cells are vital for hearing. Some of these cells amplify sounds that come into the ear, and others transform sound waves into electrical signals that travel to the brain. Ronna Hertzano, MD, PhD, Associate Professor in the Department of Otorhinolaryngology Head and Neck Surgery at UMSOM and Maggie Matern, PhD, a postdoctoral fellow at Stanford University, demonstrated that the protein, called GFI1, may be critical for determining whether an embryonic hair cell matures into a functional adult hair cell or becomes a different cell that functions more like a nerve cell or neuron.

The study was published in the journal Development, and was conducted by physician-scientists and researchers at theUMSOM Department of Otorhinolaryngology Head and Neck Surgery and the UMSOM Institute for Genome Sciences (IGS), in collaboration with researchers at the Sackler School of Medicine at Tel Aviv University in Israel.

Hearing relies on the proper functioning of specialized cells within the inner ear called hair cells. When the hair cells do not develop properly or are damaged by environmental stresses like loud noise, it results in a loss of hearing function.

In the United States, the prevalence of hearing loss doubles with every 10-year increase in age, affecting about half of all adults in their 70s and about 80 percent of those who are over age 85. Researchers have been focusing on describing the developmental steps that lead to a functional hair cell, in order to potentially generate new hair cells when old ones are damaged.

To conduct her latest study, Dr. Hertzano and her team utilized cutting-edge methods to study gene expression in the hair cells of genetically modified newborn mice that did not produce GFI1. They demonstrated that, in the absence of this vital protein, embryonic hair cells failed to progress in their development to become fully functional adult cells. In fact, the genes expressed by these cells indicated that they were likely to develop into neuron-like cells.

Our findings explain why GFI1 is critical to enable embryonic cells to progress into functioning adult hair cells, said Dr. Hertzano. These data also explain the importance of GFI1 in experimental protocols to regenerate hair cells from stem cells. These regenerative methods have the potential of being used for patients who have experienced hearing loss due to age or environmental factors like exposure to loud noise.

Dr. Hertzano first became interested in GFI1 while completing her M.D., Ph.D. at Tel Aviv University. As part of her dissertation, she discovered that the hearing loss resulting from mutations in another protein called POU4F3 appeared to largely result from a loss of GFI1 in the hair cells. Since then, she has been conducting studies to discover the role of GFI1 and other proteins in hearing. Other research groups in the field are now testing these proteins to determine whether they can be used as a cocktail to regenerate lost hair cells and restore hearing.

Hearing research has been going through a Renaissance period, not only from advances in genomics and methodology, but also thanks to its uniquely collaborative nature among researchers, said Dr. Herzano.

The new study was funded by the National Institute on Deafness and Other Communication Disorders (NIDCD) which is part of the National Institutes of Health (NIH). It was also funded by the Binational Scientific Foundation (BSF).

This is an exciting new finding that underscores the importance of basic research to lay the foundation for future clinical innovations, said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. Identifying the complex pathways that lead to normal hearing could prove to be the key for reversing hearing loss in millions of Americans.

Reference: GFI1 functions to repress neuronal gene expression in the developing inner ear hair cells by Maggie S. Matern, Beatrice Milon, Erika L. Lipford, Mark McMurray, Yoko Ogawa, Andrew Tkaczuk, Yang Song, Ran Elkon and Ronna Hertzano, 11 September 2020, Development. DOI: 10.1242/dev.186015

More here:
Protein Discovery in the Development of New Hearing Hair Cells Could Lead to Treatments for Hearing Loss - SciTechDaily

IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

By Global News Feed

MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 12, 2021 at 2:00 p.m. ET. The conference will be held in a virtual meeting format.

Go here to read the rest:
IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

By Global News Feed

CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero’s investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD).

Excerpt from:
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

By Global News Feed

SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the Guggenheim Healthcare Talks | 2021 Oncology Days on Friday, March 12, 2021 at 3 p.m. Eastern Time.

More here:
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

By Global News Feed

NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.

See the article here:
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

By Global News Feed

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET.

Excerpt from:
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

By Global News Feed

Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints

Visit link:
Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

By Global News Feed

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion’s common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “ANGN” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.

Read the original here:
Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

GBT Announces New Employment Inducement Grants

By Global News Feed

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2021, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units for an aggregate of 103,450 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

See the article here:
GBT Announces New Employment Inducement Grants

→←